US, India begin talks amid escalating trade tensions

Feb 11: China reported 108 new coronavirus deaths on February 10, the highest daily toll since the outbreak began in Wuhan late last year, as two senior officials in the hard-hit province of Hubei were removed from their jobs.

The total number of deaths on the mainland reached 1,016 in the 24 hours until midnight, the National Health Commission said on Tuesday.

Some 2,478 new cases were confirmed, bringing the total to 42,638.

Of the new deaths, 103 were in the province of Hubei, including 67 in the provincial capital of Wuhan. The virus is thought to have originated there in a market that sold seafood as well as wild animals.

Two senior health officials in the province - Zhang Jin who was Party Secretary of the health commission for Hubei and Ling Yingzi who was director of the Hubei Provincial Health Commission - were both removed from their posts, state media reported on Tuesday,  a day after Chinese President Xi Jinping visited health facilities in Beijing.

In his first public appearance since the outbreak began, Xi donned a face mask and had his temperature checked while visiting medical workers and patients in the capital.

"We have seen very little of Xi Jinping since the outbreak began but he was out and about in Beijing on Monday," Al Jazeera's Katrina Yu said from Beijing. "He has been trying to rally the troops saying: 'We can win this battle.' But it's also a sign that the battle is far from over."

The other fatalities on Monday were in the provinces of Heilongjiang, Anhui and Henan and the cities of Tianjin and Beijing, the National Health Commission said.

During a meeting chaired by Premier Li Keqiang on Monday, a group of leaders tasked with beating the virus said it would work to solve raw material and labour shortages and boost supplies of masks and protective clothing.

They said nearly 20,000 medical personnel from around the country had already been sent to Wuhan, and more medical teams were also on the way.

Jun 10: Indian-origin California Senator Kamala Harris has joined former vice president and 2020 Democratic presidential nominee Joe Biden to raise USD 3.5 million for the upcoming November elections.

Tuesday's fundraiser is the second-largest single event haul so far for the Biden campaign, which raised USD 4 million at one event earlier this month.

Harris' presence during the virtual mega fund raiser assumes significance as the Democratic Party leaders consider her to be one of the front-runners to be the nominee for vice president. The 55-year-old lawyer-politician was once considered to be a strong opponent of Biden in the 2020 Democratic primaries.

Introducing Harris to the 1,400 supporters present at the event, Biden underlined the history-breaking nature of her past electoral wins.

"For much of her career, she was the only person in the room who looked like she did," he said.

At the start of the campaign last year, Harris was very critical of Biden. She later endorsed him, months after she decided to withdraw herself from the race to the White House.

During the fundraiser, Harris was effusive in her praise for Biden.

Referring to Biden's meeting with George Floyd's family, she said, "He (Biden)is someone who whether one on one or speaking to the nation always has a sense of how people are experiencing this world, and what their needs are...This moment in the history of our country really represents an extraordinary exercise in contrast."

"On the other hand, we have a Donald Trump who had the gall to dispatch the US military to clear the streets so that he could prance down and then, like a prop, hold up the bible for a photo op," Harris said.

The death of African-American Floyd during police confinement in Minneapolis on May 25 has resulted in widespread protests not only in the US but across the world.

"There are so many contrasts between Joe Biden and Donald Trump that really point to the choice that we as Americans have today," Harris said.

California Lt Governor Eleni Kounalakis also joined the fund raiser.

In his remarks, Biden, 77, said the US is reeling in anguish and anger over the brutal killing of Floyd or the systemic racism that still infects every part of the society. "Harris knows better than anybody," he said.

"At the same time, we're facing the worst economic disaster since the Great Depression. American history is not a fairy tale with a guaranteed ending, a happy ending. This is a battle for the soul of the country.

"It's been a constant tug of war between the American ideal that we all are created equal -- and the harsh reality that racism has long torn us apart...I'm going to ask every American to look where we are now and to think, is this who we are? Is this who we want to be?" Biden asked.

Participating in the questions and answers session, Harris said America has still not fully embraced, acknowledged or addressed its history of racism and its current history of racism.

"One can think of this moment as an inflection moment, and it will require bold action and it will require immediate action...This stresses the importance and the immediacy and the urgency of electing Joe Biden," she said.

Replying to a question, Biden said, "Did you see today where the President of the United States while George Floyd was being buried, was condemning the older man who was knocked down with his head bleeding and everyone walking by. Did you see that? I mean, my lord. What have we become if we abide by this? So much we can do and must do."

Harris said the election is going to be rough and tumble.

"There are very powerful forces that thrive off of the hate and division that Donald Trump has been sowing. This is not going to be easy. And we have about just a few months to get this thing done," she said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.